`
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to
AMD
Leuven, BELGIUM - May 6, 2024 - 6:00 PM CET, Oxurion NV (Euronext Brussels:
OXUR), an innovative biopharmaceutical company based in Leuven, today announces
important progress in its preclinical program targeting Geographic Atrophy (GA),
a severe and underserved form of Age-Related Macular Degeneration (AMD).
This recently launched program has reached the first step with the
identification of 50 targets that have the potential to provide better treatment
options for GA. These targets are derived from a cutting-edge CRISPR-based
target discovery platform, which consists in a genome-wide screening in a
phenotypic cellular assay reflective of GA disease.
The preclinical team successfully already confirmed the potential of several of
these targets across various relevant in vitro models. Next step is to continue
the in vitro validation of the remaining identified targets and start their
evaluation in GA animal models.
Looking ahead, Oxurion anticipates finalizing the selection of the top three
targets in the fourth quarter of this year and to initiate the lead generation
process, aiming to file intellectual property (IP) early 2025.
Pascal Ghoson, CEO of Oxurion, shares his enthusiasm: "By moving beyond
traditional approaches focused on the complement pathway alone, our platform has
opened new avenues for understanding and treating AMD/GA. The progress we have
made paves the way for new therapies in a market estimated to be worth $3-6
billion by 2028. These advances strengthen our position to transform the
treatment of retinal degenerative diseases."
About Oxurion
Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation
standard of care ophthalmic therapies for the treatment of retinal disease.
Oxurion is headquartered in Leuven, Belgium. More information is available at
www.oxurion.com (http://www.oxurion.com)
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events, or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained in
the Company's Annual Report. This press release does not constitute an offer or
invitation for the sale or purchase of securities or assets of Oxurion in any
jurisdiction. No securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933, as amended,
or in compliance with an exemption therefrom, and in accordance with any
applicable U.S. state securities laws.
.
Contacts :
OXURION NV
Pascal Ghoson, CEO
pascal.ghoson@oxurion.com (mailto:pascal.ghoson@oxurion.com)
Â